Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Overview
Seer, Inc. is a life sciences company that is redefining proteomic research through its innovative Proteograph Product Suite. As a pioneering biotechnology firm, Seer empowers researchers with an integrated platform designed for deep, unbiased analysis of the proteome. Utilizing breakthrough nanoparticle technology, the company’s solutions enable rapid, high‐resolution proteomic profiling, providing access to biological information that was once difficult to capture.
Technology and Solutions
At the heart of Seer's offering is the Proteograph Product Suite, an end‐to‐end proteomics solution that combines proprietary engineered nanoparticles, specialized consumables, automated laboratory instrumentation, and advanced software. This integrated workflow simplifies the complex process of proteomic analysis by allowing laboratories to perform expansive analyses quickly and efficiently. The system is designed to leverage widely adopted laboratory instrumentation, making it accessible for a diverse range of users—from academic institutions to biopharmaceutical and biotechnology companies—for non‐diagnostic research purposes.
The use of engineered nanoparticles is a key differentiator, providing an unbiased approach to sample analysis that enables the detection of a vast array of proteins and peptides. This unbiased method enhances the depth and scale of proteomic studies, facilitating breakthroughs in biomarker discovery and expanding the scientific understanding of complex biological systems.
Market Position and Scientific Impact
Seer, Inc. occupies a unique niche within the life sciences industry. Its transformative products are at the intersection of proteomics and multi-omics research, driving innovation in fields such as drug discovery, biomarker identification, and precision medicine. By delivering a solution that combines high-throughput data generation with advanced analytics, Seer has established itself as a significant player among companies striving to provide researchers with comprehensive and actionable biological insights.
The company's strategic collaborations, including partnerships with renowned scientific institutions and technology companies, have further validated its technology. Through joint initiatives with global market leaders, Seer has demonstrated the ability of its Proteograph platform to significantly enhance proteomic research, thereby enabling deeper scientific inquiries and fostering knowledge across diverse research disciplines.
Collaborations and Industry Engagement
Collaboration is a cornerstone of Seer's business model. With established agreements with industry partners such as Thermo Fisher Scientific and other prominent organizations, Seer ensures that its technology is not only accessible but also continuously refined and validated in real-world research settings. These partnerships help integrate Seer's innovative platform into broader research ecosystems, facilitating joint research studies and advancing the field of proteomics through collective expertise.
Seer's active engagement in scientific conferences, collaborative research projects, and extensive publication records further underscores its commitment to pushing the boundaries of proteomic discovery. The company provides a robust support system that enables external researchers to adopt its platform with ease, ensuring that the journey from sample to data is seamless and efficient.
Operational Excellence and Value Proposition
Seer, Inc. has built its operational model on the principles of efficiency, accessibility, and scientific rigor. The Proteograph Product Suite is designed to be decentralized, allowing laboratories of various scales to integrate proteomic analysis into their existing workflows. This flexibility is crucial for academic researchers and life sciences companies alike, who demand both high throughput and precision in their analyses.
The company's focus on providing deep, unbiased insights into protein expression and function positions it as a key contributor to advancements in drug discovery and the development of novel therapeutic strategies. By offering an automated, scalable solution, Seer helps reduce the bottlenecks traditionally associated with proteomic studies, thereby accelerating research timelines and enhancing the reproducibility of findings.
Scientific Expertise and Research Integration
Seer, Inc. leverages its deep expertise in proteomics and multi-omics to facilitate a new era of scientific exploration. Its dedication to continuous innovation is reflected in the development of various protocols within the Proteograph Product Suite, which allow for the robust analysis of a plethora of sample types, including plasma, cerebrospinal fluid, and more. The ability to capture vast datasets with high sensitivity and specificity makes Seer's technology indispensable for research that aims to unravel the complexities of human biology.
Through its comprehensive research tools, Seer provides a foundation for understanding complex biological processes at a molecular level. Its platform supports endeavors in both academic research and biopharmaceutical studies, ensuring that valuable insights gained can be translated into meaningful scientific advancements without compromising on accuracy or depth.
Overall, Seer, Inc. stands out for transforming the landscape of proteomic research. Its commitment to delivering a high-quality, unbiased, and scalable analytical platform supports the scientific community in deciphering the intricate dynamics of the proteome, ultimately contributing to the broader objective of enhancing human health through targeted and informed research.
Seer (Nasdaq: SEER) reported Q4 and full year 2024 financial results. Q4 revenue was $4.0M, down 10% YoY, while full-year revenue reached $14.2M, a 15% decrease from 2023. The company shipped 10 instruments in 2024, bringing total installations to 72.
Q4 gross profit was $2.0M with 51% margin, while operating expenses increased 5% to $25.5M. Net loss widened to $21.7M in Q4 2024 from $17.8M in Q4 2023. For the full year, net loss was $86.6M compared to $86.3M in 2023.
Notable developments include a new cell lysis proteomics application for the Proteograph XT workflow and a share repurchase of 6.5M shares at $1.82/share, reducing outstanding shares by 10%. The company ended 2024 with $300M in cash and investments. For 2025, Seer projects revenue of $17-18M, representing 24% growth at midpoint.
Seer (Nasdaq: SEER), a pioneering life sciences company focused on proteomics platform commercialization, has announced its participation in the TD Cowen 45th Annual Healthcare Conference in Boston, MA.
The company's management team will engage in a fireside chat scheduled for Tuesday, March 4th at 11:50 a.m. Eastern Time (8:50 a.m. Pacific Time). Investors and interested parties can access a live webcast of the session through the Investor section of Seer's website at investor.seer.bio. An archived replay will be made available on the company's website after the conference concludes.
Seer Inc (Nasdaq: SEER) announced its participation in the 21st Annual US HUPO Conference in Philadelphia from February 22-26, 2025. The company will showcase new findings and host a seminar featuring groundbreaking research in cancer therapy using their Proteograph™ Product Suite.
The seminar will highlight Dr. Jinjun Shi's research from Brigham and Women's Hospital and Harvard Medical School, focusing on a novel co-delivery therapeutic platform that simultaneously targets cancer vulnerabilities using siRNA while activating tumor suppressors with mRNA. The study specifically addresses prostate cancer, the second leading cause of cancer death among men in the US.
Seer recently introduced a new workflow for deep cellular proteome analysis, adding to their existing 10+ Proteograph protocols for various sample types. The conference will also feature presentations from Seer and collaborators on tissue biology, cardiometabolic dysfunction biomarkers, and mass spectrometry proteomics throughput advancements.
Seer (Nasdaq: SEER) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. The life sciences company, which specializes in proteomics platform technology, will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. Investors can access the live webcast through the Investor section of Seer's website at investor.seer.bio, where an archived replay will also be available after the event.
Seer (Nasdaq: SEER), a pioneer in proteomics platform technology, has announced its participation in the J.P. Morgan 43rd Annual Healthcare Conference in San Francisco. The company's management team will deliver a presentation and engage in a Q&A session on Wednesday, January 15th at 3:00 p.m. Pacific Time / 6:00 p.m. Eastern Time.
Investors and interested parties can access a live webcast of the session through the Investor section of Seer's website at investor.seer.bio. For those unable to attend the live presentation, an archived replay will be made available on the company's website after the conference concludes.
Seer (Nasdaq: SEER) has been ranked No. 57 on the 2024 Deloitte Technology Fast 500™, achieving a remarkable 2,440% revenue growth. The company attributes this growth to increased adoption of its Proteograph Product Suite and customer discoveries across neurodegenerative disease, cancer, and metabolic disease. Key achievements include launching a technology access center in Europe, platform usage on the SpaceX Inspiration4 mission, and establishing a co-marketing agreement with Thermo Fisher Scientific. This marks Seer's second consecutive appearance on the list, improving from their No. 5 ranking in 2023.
Seer (Nasdaq: SEER) has announced its participation in two upcoming investor conferences in November. The company will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference in Boston on November 11th at 11:30 a.m. ET, and at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 21st at 10:00 a.m. ET.
Both sessions will be available via live webcast on the Investor section of Seer's website at investor.seer.bio, with archived replays accessible after the events.
Seer (NASDAQ: SEER) reported Q3 2024 financial results with revenue of $4.0 million, a 3% decrease from the prior year. Product revenue was $3.1 million, while service revenue reached $847 thousand. The company posted a gross margin of 48% and a net loss of $21.3 million. Operating expenses decreased 6% to $26.3 million. Key developments include a co-marketing agreement with Thermo Fisher Scientific, multiple research presentations at HUPO World Congress, and a $10.0 million investment in PrognomiQ. The company maintains its 2024 revenue guidance of $13-15 million and ended the quarter with $312 million in cash and investments.
Seer has announced a co-marketing and sales agreement with Thermo Fisher Scientific to jointly promote Seer's Proteograph™ Product Suite alongside Thermo Scientific Orbitrap Astral™ mass spectrometers. Under this non-exclusive agreement, Thermo Fisher's global sales force will be able to quote and sell Seer's Proteograph Product Suite starting in early 2025. The collaboration includes joint marketing activities and research studies to showcase their integrated proteomic platforms. The partnership aims to provide researchers with an integrated solution for deep, rapid, and unbiased proteomic analysis at scale.
Seer will showcase its Proteograph Product Suite at the American Society of Human Genetics (ASHG) 2024 Annual Meeting, demonstrating how deep proteomics enhances genomic research. The company will present breakthrough research in lung cancer and Alzheimer's Disease through a CoLab session featuring PrognomiQ and Salk Institute.
Key highlights include PrognomiQ's MOSAIC study, which combines proteomics with other molecular data to improve early-stage lung cancer detection, and Salk Institute's research on Relative Energy Deficiency in Sport (REDs) affecting 40% of athletes. The presentations will demonstrate how Seer's technology enables multi-omic research at unprecedented depth, scale, and speed.
FAQ
What is the current stock price of Seer (SEER)?
What is the market cap of Seer (SEER)?
What is the main focus of Seer, Inc.?
What constitutes the Proteograph Product Suite?
Who are the primary users of Seer's technology?
How does Seer enhance proteomic research?
What differentiates Seer's approach in the life sciences industry?
How does Seer collaborate with other industry players?
Is Seer's Proteograph Product Suite intended for diagnostic use?
What are the key benefits of using the Proteograph Product Suite?
